Skip to main content
. 2023 Apr 14;29(5):1103–1112. doi: 10.1038/s41591-023-02321-8

Fig. 1. Waterfall plots for percentage of tumor reductions.

Fig. 1

Tumor reduction from baseline in patients with BRAFV600E mutation-positive rare cancers by investigator assessment (a) and by independent review (b). MR, minor response; NE, not evaluable; PD, progressive disease; SD, stable disease.